CAR T-cells against BCMA for the treatment of multiple myeloma

Patent metadata

Field	Value
Publication number	US-12509525-B2
Application number	US-202017632191-A
Country	US
Kind code	B2
Filing date	Aug 3, 2020
Priority date	Aug 2, 2019
Publication date	Dec 30, 2025
Grant date	Dec 30, 2025

Abstract

The present invention provides therapeutics for the treatment of Multiple myeloma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target the B cell maturation antigen.

First claim

The invention claimed is:

1 . A chimeric antigen receptor (CAR) comprising an extracellular domain comprising a BCMA targeting-moiety, a transmembrane domain, and an intracellular signaling domain, wherein the BCMA-targeting moiety comprises a VH domain and a VL domain, wherein said VH domain and VL domain consist, respectively, of SEQ ID NO: 1 and SEQ ID NO: 2.

2 . The chimeric antigen receptor of claim 1 , wherein the BCMA-targeting moiety comprises SEQ ID NO: 3.

3 . A chimeric antigen receptor (CAR) comprising an extracellular domain comprising a BCMA targeting-moiety, a transmembrane domain, and an intracellular signaling domain, wherein the BCMA-targeting moiety is a single-chain variable fragment, comprising a VL domain and a VH domain, wherein said VH and VL domains respectively comprise SEQ ID NO: 1 and SEQ ID NO: 2.

4 . The chimeric antigen receptor of claim 3 , wherein the chimeric antigen receptor comprises:
a. the single-chain variable fragment, comprising a VL domain and a VH domain, wherein said VH and VL domains respectively comprise SEQ ID NO: 1 and SEQ ID NO: 2; b. the transmembrane domain bound to a Hinge domain comprising SEQ ID NO: 9; c. a costimulatory signaling domain comprising SEQ ID NO: 11; and d. the intracellular signaling domain comprising SEQ ID NO: 10.

5 . The chimeric antigen receptor (CAR) of claim 4 , wherein the CAR consists of SEQ ID NO: 13.

6 . A nucleic acid encoding the chimeric antigen receptor according to claim 3 .

7 . A cell comprising the nucleic acid according to claim 6 .

8 . The cell according to claim 7 , wherein the cell is a T-cell.

9 . A nucleic acid encoding the chimeric antigen receptor according to claim 1 .

10 . A cell comprising the nucleic acid according to claim 9 .

11 . The cell according to claim 10 , wherein the cell is a T-cell.

12 . A pharmaceutical composition comprising a plurality of cells according to claim 10 and a pharmaceutically acceptable carrier or diluent.

13 . A method of treating multiple myeloma, wherein the method comprises administering the cell of claim 10 , or a pharmaceutical composition comprising the cell, to a patient in need thereof.

14 . The method of claim 13 , wherein the cell is a T-cell.

15 . An immunoglobulin binding protein comprising a BCMA targeting-moiety, wherein the BCMA-targeting moiety comprises a VH domain and a VL domain, wherein said VH domain and VL domain consist, respectively, of SEQ ID NO: 1 and SEQ ID NO: 2.

16 . The immunoglobulin binding protein of claim 15 , wherein the BCMA-targeting moiety comprises SEQ ID NO: 3.

17 . The immunoglobulin binding protein of claim 15 , wherein the BCMA-targeting moiety is an antibody, a single-chain variable fragment, an antigen-binding fragment, a single-chain antigen-binding fragment, or a single-chain fusion protein.

Assignees

• Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer
• Hospital Clinic Barcelona
• Univ Barcelona

Inventors

• Martín Antonio Beatriz
• Urbano Ispizua Álvaro
• Pérez Amill Lorena
• Suñe Rodriguez Guillermo
• Juan Otero Manel

Classifications

• A61K40/4215

  Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/46

  characterised by the cancer treated · CPC title

• C07K2319/03

  containing a transmembrane segment · CPC title